Metabolism of doxorubicin to the cardiotoxic metabolite doxorubicinol is increased in a mouse model of chronic glutathione deficiency: A potential role for carbonyl reductase 3

Chemico-Biological Interactions

Volumn 234, Issue , 2015, Pages 154-161

  Schaupp, Christopher M ^a   White, Collin C ^a   Merrill, Gary F ^b   Kavanagh, Terrance J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

Carbonyl reductase; Cardiotoxicity; Doxorubicin; Glutathione deficiency; Pharmacogenetics

Indexed keywords

CARBONYL REDUCTASE; CARBONYL REDUCTASE 3; DOXORUBICIN; DOXORUBICINOL; EPIRUBICIN; UNCLASSIFIED DRUG; ALCOHOL DEHYDROGENASE; GLUTATHIONE; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN DEFICIENCY; UPREGULATION; ANIMAL; CELL LINE; COCULTURE; DEFICIENCY; DISEASE MODEL; GENETICS; LIVER; LIVER CELL; METABOLISM; MYOBLAST; RAT;

MURINAE; MUS; RATTUS;

ALCOHOL OXIDOREDUCTASES; ANIMALS; CARDIOTOXICITY; CELL LINE; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; DOXORUBICIN; FEMALE; GLUTATHIONE; HEPATOCYTES; LIVER; MICE; MYOBLASTS; RATS; RNA, MESSENGER;

EID: 84928407585     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2014.11.010     Document Type: Article

References (19)

1. S.E. Lipshultz, T.R. Cochran, V.I. Franco, and T.L. Miller Treatment-related cardiotoxicity in survivors of childhood cancer Nat. Rev. Clin. Oncol. 10 12 2013 697 710
2. P.K. Singal, and N. Iliskovic Doxorubicin-induced cardiomyopathy N. Engl. J. Med. 339 13 1998 900 905
3. J.G. Blanco, C.L. Sun, W. Landier, L. Chen, D. Esparza-Duran, W. Leisenring, A. Mays, D.L. Friedman, J.P. Ginsberg, M.M. Hudson, J.P. Neglia, K.C. Oeffinger, A.K. Ritchey, D. Villaluna, M.V. Relling, and S. Bhatia Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes - a report from the Children's Oncology Group J. Clin. Oncol. 30 13 2012 1415 1421
4. L.C.M. Kremer, and H. Caron Anthracycline cardiotoxicity in children N. Engl. J. Med. 351 2004 120 121
5. R.J. Boucek, R.D. Olson, D.E. Brenner, E.M. Ogunbunmi, M. Inui, and S. Fleischer The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions J. Biol. Chem. 262 33 1987 15851 15856
6. R.D. Olson, P.S. Mushlin, D.E. Brenner, S. Fleischer, B.J. Cusack, B.K. Chang, and R.J. Boucek Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol Proc. Natl. Acad. Sci. U.S.A. 85 10 1988 3585 3589
7. N. Kassner, K. Huse, H.J. Martin, U. Gödtel-Armbrust, A. Metzger, I. Meineke, J. Brockmöller, K. Klein, U.M. Zanger, E. Maser, and L. Wojnowski Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver Drug Metab. Dispos. 36 10 2005 2113 2120
8. U. Oppermann Carbonyl reductases: the complex relationships of mammalian carbonyl- and quinone-reducing enzymes and their role in physiology Annu. Rev. Pharmacol. Toxicol. 47 2007 293 322
9. L. Fan, B.C. Goh, C.I. Wong, N. Sukri, S.E. Lim, S.H. Tan, J.Y. Guo, R. Lim, H.L. Yap, Y.M. Khoo, F. Iay, H.S. Lee, and S.C. Lee Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity Pharmacogenet. Genomics 18 7 2008 623 631
10. J.M. Lubieniecka, J. Liu, D. Heffner, J. Graham, R. Reid, D. Hogge, T.A. Grigliatti, and W.K. Riggs Single-nucleotide polymorphisms in aldo-keto and carbonyl reductase genes are not associated with acute cardiotoxicity after daunorubicin chemotherapy Cancer Epidemiol. Biomarkers Prev. 21 11 2012 2118 2120
11. O.S. Bains, M.J. Karkling, J.M. Lubieniecka, T.A. Grigliatti, R.E. Reid, and K.W. Riggs Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism J. Pharmacol. Exp. Ther. 332 3 2010 755 763
12. L.A. McConnachie, I. Mohar, F.N. Hudson, C.B. Ware, W.C. Ladiges, C. Fernandez, S. Chatterton-Kirchmeier, C.C. White, R.H. Pierce, and T.J. Kavanagh Glutamate cysteine ligase modifier subunit deficiency and gender as determinants of acetaminophen-induced hepatotoxicity in mice Toxicol. Sci. 99 2 2007 628 636
13. J.A. Haque, R.S. McMahan, J.S. Campbell, M. Shimizu-Albergine, A.M. Wilson, D. Botta, T.K. Bammler, R.P. Beyer, T.J. Montine, M.M. Yeh, T.J. Kavanagh, and N. Fausto Attenuated progression of diet-induced steatohepatitis in glutathione-deficient mice Lab. Invest. 90 12 2010 1704 1717
14. A.A. Bondareva, M.R. Capecchi, S.V. Iverson, Y. Li, N.I. Lopez, O. Lucas, G.F. Merrill, J.R. Prigge, A.M. Siders, M. Wakamiya, S.L. Wallin, and E.E. Schmidt Effects of thioredoxin reductase-1 deletion on embryogenesis and transcriptome Free Radic. Biol. Med. 43 6 2007 911 923
15. J. Carmichael, W.G. Degraff, A.F. Gazdar, J.D. Minna, and J.B. Mitchell Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing Cancer Res. 47 1987 936
16. J.G. Blanco, W.M. Leisenring, V.M. Gonzalez-Covarrubias, T.I. Kawashima, S.M. Davies, M.V. Relling, L.L. Robison, C.A. Sklar, M. Stovall, and S. Bhatia Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H: quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer Cancer 112 12 2008 2789 2795
17. D. Jamieson, and A.V. Boddy Pharmacogenetics of genes across the doxorubicin pathway Expert Opin. Drug Metab. Toxicol. 7 10 2011 1201 1210
18. B. Ebert, M. Kisiela, P. Malátková, Y. El-Hawari, and E. Maser Regulation of human carbonyl reductase 3 (CBR3; SDR21C2) expression by Nrf2 in cultured cancer cells Biochemistry 49 39 2010 8499 8511
19. C.A. Hudis Trastuzumab - mechanism of action and use in clinical practice N. Engl. J. Med. 357 1 2007 39 51